NUVL vs ASR Comparison

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Grupo Aeroportuario del Sureste SAB de CV and its subsidiaries hold concessions to operate, maintain, and develop airports in the southeast region of Mexico. As an operator of airports, it charges airlines, passengers, and other users fees for using the airports' facilities. The group also derives rental and other income from commercial activities conducted at its airports, such as the leasing of space to restaurants and retailers. The company's operating segments are Cancun, which generates majority revenue, Aerostar, Airplan, Merida, Villahermosa, Holding and Services, and Others.